0000000000535787
AUTHOR
Harry Sokol
showing 16 related works from this author
Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.
2013
International audience; OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who were enrolled from May 2004 to June 2005, and followed-up until December 2007, we identified 405 patients with cancer diagnosed previous to study entry. We calculated the rates of incident cancer in patients with or without previous cancer, and we assessed by survival analysis and nested case-control study the impact of immunosuppressants on the risk of incident new or recurrent cancer in patients with previous cancer. RESULTS: The rate of incid…
Additional file 6 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 6. (A) Sorensen similarity index between donor and recipient fecal microbiota 6 weeks after FMT or sham, separating “FMT” failure from “FMT success”.
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastri…
2021
International audience; Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane. Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months). The first results of immune checkpoint inhibitors (anti-PD-1) combined with chemotherapy in metastatic gastric and GEJ cancers were discordant in recent phase III trials. Data on dual-blockade (anti-PD-L1 or anti-PD-1 plus anti-CTLA-4) plus chemotherapy are lacking. DURIGAST is a randomised, multicenter, non-c…
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.
2012
International audience; BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess…
Additional file 10 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 10. Clinical efficacy of FMT is associated with colonization by the donor microbiota. Flare-free survival of patients in the FMT and the Sham groups.
Additional file 9 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 9. Evolution of similarity index (1-unweighted Unifrac) between donor and recipient fecal microbiota in patients with FMT success and FMT failure.
Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…
Additional file 2 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 2. Screening measures for donors.
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.
2016
International audience; The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on intestinal bacteria. How and which relevant bacterial species are involved in tumor immunosurveillance, and their mechanism of action are unclear. Here, we identified two bacterial species, Enterococcus hirae and Barnesiella intestinihominis that are involved during CTX therapy. Whereas E. hirae translocated from the small intestine to secondary lymphoid organs and increased the intratumoral CD8/ Treg ratio, B. intestinihominis accumulated in the colon and promoted the infiltration of IFN-gamma-producing gamma delta Tau cells in cancer lesions. The immune sensor, NOD2, limited CTX…
Additional file 5 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 5. Change in clinical and biological parameters between day 0 and week 6 for FMT and sham treatment groups.
Additional file 4 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 4. Characteristics of patients at selection (before starting corticosteroids.
Impact of probiotics on risk factors for cardiovascular diseases. A review.
2014
International audience; Probiotic microorganisms have historically been used to rebalance disturbed intestinal microbiota and to diminish gastrointestinal disorders, such as diarrhea or inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis). Recent studies explore the potential for expanded uses of probiotics on medical disorders that increase the risk of developing cardiovascular diseases and diabetes, such as obesity, hypercholesterolemia, arterial hypertension, and metabolic disturbances such as hyperhomocysteinemia and oxidative stress. This review aims at summarizing the proposed molecular and cellular mechanisms involved in probiotic-host interactions and to identi…
Additional file 1 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 1: Study design.
Additional file 8 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 8. Abundance of taxa at the genus/species level during the follow-up period in patients with FMT success (A) and FMT failure (B). Proportion of different OTU from donors in patients with FMT success and FMT failure (C). Only taxa representing > 0.1% of the microbiota were taken into account in the analysis.
Additional file 7 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 7. Principal coordinate analysis of Bray–Curtis distance in patients with FMT failure (A) or FMT sucess (B). Each PCoA plot represent the samples from a single patient across the different time points. PC1, PC2 and PC3 represent the top three principal coordinates that captured most of the diversity. The fraction of diversity captured by the coordinate is given as a percentage.
Additional file 3 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
2020
Additional file 3. Raw sequence data.